The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should followed?
1. Discuss possible strategies that brands in general, and branded drugs in particular, can use to fight generic products. 2. Provide an introduction to the marketing of pharmaceutical products. 3. Discuss the value of branding for professional buyers (expert who prescribe the product as opposed to non-expert who use or consume the product).
- Brand management
- Pharmaceutical products
- Prescription drugs
- Generic drugs
- Private labels
- Pharmaceutical and Medical Device Sectors